8-K filed Aug 10, 2026 at 16:05 ET
Enanta reported a narrower-than-expected net loss of $0.45 per share for fiscal Q2 2026, beating the consensus estimate of -$0.51 by 11.8%, while revenue of $17.2M exceeded the $16.8M consensus, driven by higher AbbVie royalty revenue; the company also initiated dosing in a Phase 1 trial of EDP-978 and advanced its RSV pipeline toward a registrational trial, reinforcing its clinical-stage catalyst trajectory.